Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project

Amatu, 2019, Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer, Ann. Oncol, 30, 10.1093/annonc/mdz383 Indo, 1996, Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis, Nat. Genet, 13, 485, 10.1038/ng0896-485 Greco, 2000, The Gly571Arg mutation, associated with the autonomic and sensory disorder congenital insensitivity to pain with anhidrosis, causes the inactivation of the NTRK1/nerve growth factor receptor, J. Cell Physiol, 182, 127, 10.1002/(SICI)1097-4652(200001)182:1<127::AID-JCP14>3.0.CO;2-0 Klein, 1993, Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death, Cell, 75, 113, 10.1016/S0092-8674(05)80088-1 Xu, 2003, Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor, Nat. Neurosci, 6, 736, 10.1038/nn1073 Yeo, 2004, A de novo mutation affecting human TrkB associated with severe obesity and developmental delay, Nat. Neurosci, 7, 1187, 10.1038/nn1336 Huang, 2001, Neurotrophins: roles in neuronal development and function, Annu. Rev. Neurosci, 24, 677, 10.1146/annurev.neuro.24.1.677 Vaishnavi, 2015, TRKing down an old oncogene in a new era of targeted therapy, Cancer Discov, 5, 25, 10.1158/2159-8290.CD-14-0765 Forsythe, 2020, A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors, Ther. Adv. Med. Oncol, 12, 10.1177/1758835920975613 Bourgeois, 2000, Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors, Am. J. Surg. Pathol, 24, 937, 10.1097/00000478-200007000-00005 Bishop, 2013, Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma, Hum. Pathol, 44, 1982, 10.1016/j.humpath.2013.03.017 Vaishnavi, 2013, Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer, Nat. Med, 19, 1469, 10.1038/nm.3352 Stransky, 2014, The landscape of kinase fusions in cancer, Nat. Commun, 5, 4846, 10.1038/ncomms5846 Drilon, 2019, TRK inhibitors in TRK fusion-positive cancers, Ann. Oncol, 30, 10.1093/annonc/mdz282 Laetsch, 2021, Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer, Clin. Cancer Res, 27, 4974, 10.1158/1078-0432.CCR-21-0465 Bayer HealthCare Pharmaceuticals Inc. VITRAKVI prescribing information, 2021, [Internet]. [cited August 16, 2021]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210861s006lbl.pdf. Bayer A.G. VITRAKVI summary of product characteristics, 2021, [Internet]. [cited August 23, 2021]. Available from https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf. Hong, 2020, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Lancet Oncol, 21, 531, 10.1016/S1470-2045(19)30856-3 Drilon A.E., Hong D.S., Tilburg CMv, Doz F., Tan D.S.W., Kummar S., et al. Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer. J Clin Oncol 40 (2022);no. 16_suppl:3100-3100. Genentech. Rozlytrek US prescribing information, 2021, [Internet]. [cited]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf. Menichincheri, 2016, Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor, J. Med. Chem, 59, 3392, 10.1021/acs.jmedchem.6b00064 Doebele, 2020, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials, Lancet Oncol, 21, 271, 10.1016/S1470-2045(19)30691-6 Bazhenova, 2021, TRK fusion cancer: patient characteristics and survival analysis in the real-world setting, Target Oncol, 16, 389, 10.1007/s11523-021-00815-4 Rosen, 2020, TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations, Clin. Cancer Res, 26, 1624, 10.1158/1078-0432.CCR-19-3165 Genomics England. The national genomics research and healthcare knowledgebase v6, 2019, [Internet]. [cited May 14 2021,]. Available from https://doi.org/10.6084/m9.figshare.4530893.v5. National Health Service. Hospital episode statistics (HES), [Internet]. [cited May 14 2021, 2021 ]. Available from https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics. Public Health England. National cancer registration and analysis service (NCRAS), [Internet]. [cited May 14 2021, 2021 ]. Available from https://www.cancerdata.nhs.uk/. Office for National Statistics. Office for national statistics (ONS), [Internet]. [cited May 14 2021 , 2021]. Available from https://www.ons.gov.uk/. Genomics England. Cancer Eligibility Statement, 2018, [Internet]. [cited October 26 2021,]. Available from https://www.genomicsengland.co.uk/wp-content/uploads/2018/04/Cancer-Eligibility-Criteria-v4.pdf. Chen, 2016, Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications, Bioinformatics, 32, 1220, 10.1093/bioinformatics/btv710 Mahalanobis, 1936, On the generalised distance in statistics, Proc. Natl. Inst. Sci. India, 2, 49 Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J. Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8 Archer DX Inc. Quiver database, 2021, [Internet]. [cited March 12, 2021 2021]. Available from http://quiver.archerdx.com. Stuart, 2013, Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research, J. Clin. Epidemiol, 66, S84, 10.1016/j.jclinepi.2013.01.013 Austin, 2011, An introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivariate Behav. Res, 46, 399, 10.1080/00273171.2011.568786 Farago, 2018, Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion, JCO Precis. Oncol, 10.1200/PO.18.00037 Pietrantonio, 2017, ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer, J. Natl. Cancer Inst, 109, 10.1093/jnci/djx089 Westphalen, 2021, Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population, NPJ Precis. Oncol, 5, 69, 10.1038/s41698-021-00206-y Fabrizio, 2018, Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition, J. Gastrointest. Oncol, 9, 610, 10.21037/jgo.2018.05.06 Bonneville, 2017, Landscape of microsatellite instability across 39 cancer types, JCO Precis. Oncol, 10.1200/PO.17.00073 Chou, 2020, NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases, Mod. Pathol, 33, 924, 10.1038/s41379-019-0417-3 Cocco, 2019, Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions, Cancer Res, 79, 1047, 10.1158/0008-5472.CAN-18-3126 Madison, 2022, Clustered 8-oxo-guanine mutations and oncogenic gene fusions in microsatellite-unstable colorectal cancer, JCO Precis. Oncol, 6 Ross, 2018, NTRK fusions in breast cancer: clinical, pathologic and genomic findings, Cancer Res, 78, 09, 10.1158/1538-7445.SABCS17-P2-09-15 Hsiao, 2019, Aisner DL. Detection of tumor NTRK gene fusions to identify patients who may benefit from TRK inhibitor therapy, J. Mol. Diagn, 10.1016/j.jmoldx.2019.03.008 Benayed, 2019, High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden, Clin. Cancer Res, 25, 4712, 10.1158/1078-0432.CCR-19-0225 Tognon, 2002, Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma, Cancer Cell, 2, 367, 10.1016/S1535-6108(02)00180-0 Leeman-Neill, 2014, ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer, Cancer, 120, 799, 10.1002/cncr.28484 Schram, 2022, Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers, J. Clin. Oncol, 40, 105, 10.1200/JCO.2022.40.16_suppl.105 (NICE) NIfHaCE. Larotrectinib for treating NTRK fusion-positive solid tumours, 2020, [Internet]. [cited]. Available from https://www.nice.org.uk/guidance/TA630/chapter/1-Recommendations. (NICE) NIfHaCE. Entrectinib for treating NTRK fusion-positive solid tumours, 2020, [Internet]. [cited]. Available from https://www.nice.org.uk/guidance/TA644/chapter/1-Recommendations.